In this retrospective study, we analysed serum biomarkers of 381 IPMN patients and found that patients with malignant IPMNs had higher serum CA19-9, CA125 and CEA levels. The gene discussed is CEACAM5; the disease is pancreatic intraductal papillary-mucinous neoplasm.